April 27, 2020 / 1:31 PM / in a month

BRIEF-Theratechnologies Announces New Positive Results For Two Investigational Peptide-Drug Conjugates

April 27 (Reuters) - Theratechnologies Inc:

* THERATECHNOLOGIES ANNOUNCES NEW POSITIVE RESULTS FOR TWO INVESTIGATIONAL PEPTIDE-DRUG CONJUGATES TARGETING SORTILIN POSITIVE OVARIAN CANCER

* THERATECHNOLOGIES - COMPARED TO TREATMENTS USING DOXORUBICIN OR DOCETAXEL, TH1902 AND TH1904 WERE BOTH FOUND TO HAVE BETTER EFFICACY

* THERATECHNOLOGIES INC - INTENDS TO INITIATE, BY END OF 2020, A FIRST-IN-HUMAN CLINICAL TRIAL WITH TH1902 IN CANCER PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below